Navigation Links
KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH
Date:11/7/2013

titute
  • Location: Ernest N. Morial Convention Center, Hall E.
  • Additional Abstracts

    In addition to the abstract accepted for presentation, two additional abstracts describing  EphA3 expression and screening in myeloid malignancies were accepted for publication online and in the ASH conference materials. These abstracts outline An Immunohistochemistry (IHC) Screen For EphA3 Positive Tumors and Analysis of EphA3 Expression in Hematologic Malignancies by Quantitative PCR.

    "These published abstracts further detail our ongoing research efforts on EphA3," stated Dr. Geoffrey Yarranton, Chief Scientific Officer and Executive Vice President of Research and Development at KaloBios. "We continue to work to understand EphA3 expression on various tumor types, and we now have a validated EphA3 screening test operative at a CLIA laboratory to screen patients' tumor biopsies before entry into the Phase 2 portion of Study KB004-01 in AML and MDS."

    About KaloBios

    KaloBios Pharmaceuticals, Inc. is developing a portfolio of proprietary, patient-targeted, first-in-class monoclonal antibodies designed to treat severe life-threatening or debilitating diseases for which there is an unmet medical need, with a clinical focus on severe respiratory diseases and cancer.

    Currently, KaloBios has three drug development programs:

    • KB003, an anti-GM-CSF mAb with potential to treat inflammatory diseases, being developed for the treatment of severe asthma. Enrollment of 160 patients has been completed in a Phase 2 study in the United States, Europe and Australia.
    • KB001-A, an anti-PcrV mAb fragment that is partnered exclusively with Sanofi Pasteur and is being developed for the prevention and treatment of Pa infections. KaloBios has retained right
      '/>"/>

    SOURCE KaloBios Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology news :

    1. Cell therapy using patients own bone marrow may present option for heart disease
    2. Report presents designs for study of cancer risks near US nuclear facilities
    3. Entomology 2012 to present 105 insect symposia in November
    4. NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards
    5. The Brain Prize 2012 is presented May 9th
    6. Validity CTO to Present Natural ID Solutions for Improving Mobile Risk Management and User Experience at NFC Solutions Summit 2012
    7. John Theurer Cancer Center presents significant blood cancer research at 2012 ASCO Annual Meeting
    8. Amarantus BioSciences to Present at the National Investment Banking Associations (NIBA)122nd Conference in New York City
    9. Coral reef experts to present latest coral reef science during July symposium
    10. FirstMark Exhibiting and Presenting at the San Diego Academy of Family Physicians 55th Annual Postgraduate Symposium
    11. GSA Bulletin presents studies in Antarctica, Italy, Mexico, Algeria, Mongolia, and more
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/23/2014)... are packed with healthful compounds, and now lab tests ... as prescription anti-diabetic medication, scientists report. In their new ... Food Chemistry , they found that how the herbs ... which compounds contribute the most to this promising trait. ... that in 2012, type-2 diabetes affected more than 8 ...
    (Date:7/23/2014)... Basement membrane degradation and blood-brain barrier damage ... and brain functioning. Matrix metalloproteinase-9 is able ... basement membrane around cerebral blood vessels and ... Huilian Hou and colleagues from the First ... Jiaotong University, China induced cerebral infarction in ...
    (Date:7/23/2014)... hippocampal region of the brain is important ... However, the underlying mechanisms are unclear. Dr. ... China monitored the activity of hippocampal neurons ... the mechanisms underlying the neuronal responses. Somatosensory ... changed local field potentials into theta rhythm-dominated ...
    Breaking Biology News(10 mins):
    ... Attendance on Demand,web-hosted employee time and attendance service ... time clock. The unique data,collection device is Internet-ready, ... the web hosted employee time tracking system,Attendance on ... complex set-up,needed., The HP WebNet, available exclusively ...
    ... developed a potentially powerful new tool in the fight ... diseases, including blindness, in 40 million children annually, and ... in developing countries. This tool consists of ... corn that will enable developing countries to identify and ...
    ... species are those that occur outside their natural range ... They can be plants, animals or microorganisms that are ... through tourism, travel or trade, or when domestic animals ... to the rising cost of invasive species on a ...
    Cached Biology News:Web-Hosted Attendance on Demand(R) Introduces Innovative Web Time Clock 2New way to produce high-vitamin corn could improve nutrition in developing countries 2New way to produce high-vitamin corn could improve nutrition in developing countries 3Scientists call for urgent research into 'real' impacts of invasive species 2Scientists call for urgent research into 'real' impacts of invasive species 3
    (Date:7/23/2014)... July 23, 2014 Adult stem ... therapies are biological, but not magical. However, ... to treat them as if they were magical. ... unsanctioned studies that constitute “stem cell tourism,” are ... approach to developing new regenerative medicine therapies. In ...
    (Date:7/22/2014)... (PRWEB) July 23, 2014 The ... , The goal of the Symposium is ... spectrum of scientists working in the biomaterials field, ... that represent the most promising directions for ultimate ...     Provide faculty and government scientists with ...
    (Date:7/22/2014)... Even within a phylum so full of mean little creatures, ... for its cruelty -- at least to crickets. Native to ... a most predatory sort of parasite. It swoops onto the ... larvae, and leaves its wicked brood to invade, kill and ... this would be possible without the fly,s ability to find ...
    (Date:7/22/2014)... Vibrate a solution of rod-shaped metal nanoparticles in water ... like tiny drill bits. Why? No one yet knows ... and Technology (NIST) have clocked their speedand it,s fast. ... rotate 10 times faster than any nanoscale object submerged ... dizzying rate has opened up the possibility that they ...
    Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 2The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 3The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 4The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 5The 2014 NJ Symposium on Biomaterials Science Earns Society for Biomaterials Endorsement 2Fly-inspired sound detector 2Fly-inspired sound detector 3Fly-inspired sound detector 4NIST shows ultrasonically propelled nanorods spin dizzyingly fast 2
    ... Oct. 12 Spherix Incorporated (Nasdaq: SPEX ... metabolic syndrome and atherosclerosis; and providers of technical and ... companies, today announced the close of previously reported agreements ... B Convertible Preferred Stock and warrants to purchase shares ...
    ... 12 US Oncology, Inc., the nation,s ... enrolled the 1,000th patient in a Phase I clinical ... Phase I clinical trials present special challenges, including increased ... trial designs, and some first-in-human trials, making Phase I ...
    ... SCOTTSDALE, AZ, Oct. 12 /PRNewswire/ - Dynamic Ventures ... the Editorial Board of Standard and Poor,s ("S&P") ... Records Market Access Program. Standard & Poor,s Corporation ... on U.S. and international public companies by investors ...
    Cached Biology Technology:Spherix Announces Closing of Institutional Investors Purchase of $5.25 Million of Convertible Preferred Stock and Warrants 2Spherix Announces Closing of Institutional Investors Purchase of $5.25 Million of Convertible Preferred Stock and Warrants 3US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 2US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 3US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 4US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 5Dynamic Ventures Corporation's Information To Be Available Through Standard & Poor's Market Access Program 2
    Mouse monoclonal [0.N.509] to PCTAIRE2 ( Abpromise for all tested applications). entrezGeneID: 5128 SwissProtID: Q00537...
    Rabbit Anti-Human Secretory Carrier Membrane Protein 2 (SCAMP2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: Western Blot...
    Parathyroid Hormone Receptor 2 [PTHR2]...
    ... Desalt Spin Columns contain a proprietary high-performance ... exceptional desalting and protein-recovery characteristics compared to ... low as 25 g/ml of protein can ... > 95% retention of salts and other ...
    Biology Products: